Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases

Journal of Cancer Research and Clinical Oncology

Volumn 143, Issue 6, 2017, Pages 1075-1082

  Udagawa, Hibiki ^a   Niho, Seiji ^a   Kirita, Keisuke ^a   Umemura, Shigeki ^a   Matsumoto, Shingo ^a   Yoh, Kiyotaka ^a   Goto, Koichi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Bone metastases; Chemotherapy; Denosumab; Non small cell lung cancer; Survival

Indexed keywords

AFATINIB; ANTIBIOTIC AGENT; CREATININE; CRIZOTINIB; DENOSUMAB; ERLOTINIB; GEFITINIB; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SPINAL CORD COMPRESSION; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; SECONDARY; SURVIVAL ANALYSIS;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DENOSUMAB; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 85013151823     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-017-2350-5     Document Type: Article

References (14)

1. Daniele S et al (2015) Natural history of non-small-cell lung cancer with bone metastases. Sci Rep 5:18670 doi:10.1038/srep18670
2. Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England: 1990) 45:228–247 doi:10.1016/j.ejca.2008.10.026
3. Garraway IP (2013) Targeting the RANKL pathway: putting the brakes on prostate cancer progression in bone. J Clin Oncol 31:3838–3840. doi:10.1200/jco.2013.50.1544
4. Henry DH et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132. doi:10.1200/jco.2010.31.3304
5. Kitazawa S, Kitazawa R (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198:228–236. doi:10.1002/path.1199
6. Peng X et al (2013) Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PloS One 8:e58361. doi:10.1371/journal.pone.0058361
7. Riihimaki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K (2014) Metastatic sites and survival in lung cancer. Lung Cancer 86:78–84 doi:10.1016/j.lungcan.2014.07.020
8. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664. doi:10.1056/NEJMra030831
9. Rosen LS et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind placebo-controlled trial. Cancer 100:2613–2621. doi:10.1002/cncr.20308
10. Scagliotti GV et al (2012) Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 7:1823–1829. doi:10.1097/JTO.0b013e31826aec2b
11. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30. doi:10.3322/caac.21166
12. Smith MR et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised placebo-controlled trial. Lancet 379:39–46. doi:10.1016/s0140-6736(11)61226-9
13. Smith MR et al (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800–3806. doi:10.1200/jco.2012.44.6716
14. Stopeck AT et al (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer Supportive care in cancer: official journal of the Multinational Association of. Supp Care Cancer 24:447–455. doi:10.1007/s00520-015-2904-5